Literature DB >> 109196

Variable oral absorption of hexamethylmelamine in man.

M D'Incalci, G Bolis, C Mangioni, L Morasca, S Garattini.   

Abstract

Plasma levels of hexamethylmelamine were measured by a sensitive and specific gas chromatographic assay in 11 patients after they received oral doses ranging from 120 to 300 mg/m2. Peak levels were reached in 0.5--3 hours and ranged from 0.2 to 20.8 micrograms/ml. The area under the curve ranged from 70.2 to 3606.6 micrograms/ml x minute. The half-life of the beta-phase of elimination also showed considerable variability, ranging between 4.66 and 10.2 hours. These parameters were not related to the dose administered. No plasma accumulation of the drug was observed after daily treatment with hexamethylmelamine for 14--21 days.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 109196

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  18 in total

1.  Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.

Authors:  E Boven; M M Nauta; H M Schlüper; C A Erkelens; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

3.  Metabolism of hexamethylmelamine in mice.

Authors:  I R Judson; C J Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 6.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 7.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Human central nervous system pharmacology of pentamethylmelamine and its metabolites.

Authors:  D J Stewart; J A Benvenuto; M Leavens; R G Smith; F Cabanillas; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 9.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

Authors:  E Garattini; T Colombo; M G Donelli; P Catalani; M Bianchi; M D'Incalci; C Pantarotto
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.